Top Markets
Coin of the day
Abliva AB (publ) Abliva AB (publ)

Abliva AB (publ)

ABLI
Clasificación en acciones #22998
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000,... Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Precio por acción
$0.04959193
Última sincronización: 2025-03-17
Capitalización bursátil
$79.94M
Cambio (1 día)
13.49%
Cambio (1 año)
0.00%
País
SE
Comercio Abliva AB (publ) (ABLI)

Categoría

Historial del precio de la acción de Abliva AB (publ) (ABLI)
Precio más alto de cierre: $0.04 el 2025-03-01

Precio más bajo de cierre: $0.44 el 2008-10-01
Historial del precio de la acción de Abliva AB (publ) desde 2008 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2025 83.38%
2024 -0.37%
2023 44.87%
2022 -73.02%
2021 -34.26%
2020 -30.47%
2019 -20.24%
2018 -46.40%
2017 4.60%
2016 -62.61%
2015 -86.83%
2014 208.88%
2013 -8.57%
2012 59.62%
2011 -55.60%
2010 208.76%
2009 91.09%
2008 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH